IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction Transcript
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
Ionis Climbs As FDA Clears New Therapy To Lower Triglycerides, Pancreatitis Risk
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Ionis Pharmaceuticals, Inc. (IONS) Discusses Progress in RNA Therapeutics and Transition to Commercial-Stage Biotechnology Transcript
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?
Ionis Pharmaceuticals: Bull Run Can Continue As Major Catalysts Approach
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
Ionis Pharmaceuticals, Inc. (IONS) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease
Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
GSK Targets China's Hepatitis B Market Through New Deal
Tweedy Browne's Strategic Moves: Ionis Pharmaceuticals Inc. Sees Significant Reduction
Ionis to host 2026 virtual Annual Meeting of Stockholders
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis reports first quarter 2026 financial results and highlights progress on key programs
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $73,013.92 in Stock
B Lynne Parshall Sells 5,000 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
Kyle Jenne Sells 4,902 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
Ionis Pharmaceuticals (NASDAQ:IONS) and Akebia Therapeutics (NASDAQ:AKBA) Financial Analysis
Ionis to hold first quarter 2026 financial results webcast
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Aberdeen Group plc
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by SG Americas Securities LLC
Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106
DAVENPORT & Co LLC Purchases 155,334 Shares of Ionis Pharmaceuticals, Inc. $IONS
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative
Elizabeth Hougen Sells 215,048 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock